GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head ...

The company’s consolidated profit excluding minority interest dropped to EGP 105.826 million in January-September from EGP 46.728 million a year earlier ...

GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...

GSK PLC GSK shares inched down 0.55% to £13.62 Wednesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.06% to 8,030.33. Supported ...

Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in ...

GSK-sponsored survey reveals unique gaps in care and support facing patients with gynaecologic cancers: London, UK Thursday, November 14, 2024, 15:00 Hrs [IST] GSK plc announced t ...